← Back
$ONC All transactions

BeOne Medicines Ltd.

M 10b5-1 Plan

$ Value

$21K

Shares

110

Price

$194

Filed

Mar 13

Insider

Name

Lee Chan Henry

Title

SVP, General Counsel

CIK

0001980648

Roles

Officer

Transaction Details

Transaction Date

2026-03-11

Code

M

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

110

Footnotes

Each American Depositary Share represents 13 Ordinary Shares. | The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. | The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. | These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. | These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. | These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Filing Info

Accession No.

0001980648-26-000008

Form Type

4

Issuer CIK

0001651308

Lee Chan Henry's History

Date Ticker Type Value
2026-04-08 ONC M $20K
2026-04-08 ONC M $28K
2026-04-08 ONC M $16K
2026-04-08 ONC $103K
2026-04-08 ONC M $0
2026-04-08 ONC M $0
2026-04-08 ONC M $0
2026-03-11 ONC M $21K
2026-03-11 ONC M $28K
2026-03-11 ONC M $16K

Other Insiders at ONC (90d)

Insider Bought Sold Last
OYLER JOHN
Chief Executive Officer
2026-03-06
Wu Xiaobin
President and COO
2026-03-06
Wang Lai
President, Global Head of R&D
2026-03-06
Lee Chan Henry
SVP, General Counsel
$786K 2026-04-08
Rosenberg Aaron
Chief Financial Officer
2026-03-06